Traders should monitor upcoming Phase 1b/2 data in 1H 2027 as the next major catalyst. The strong cash runway de-risks near-term financing risk, supporting a hold or accumulate position ahead of clinical readouts.
Price Chart
Executive Summary
Kalaris Therapeutics reported financial results for 2025, highlighted by positive Phase 1a data for its nAMD candidate TH103, a $50.0 million private placement, and a significant cash position of $118.0 million that funds operations into Q4 2027. Despite reduced net loss, the company remains pre-revenue with no near-term earnings inflection, but clinical milestones ahead could drive value.
Key Financial Metrics
Key Facts
- Positive Phase 1a data for TH103 in nAMD: mean 10-letter BCVA improvement, 129μm CST reduction, and favorable pharmacokinetics with 27-51x lower systemic exposure vs. current anti-VEGF agents.
- Completed $50.0 million private placement in December 2025, contributing to $118.0 million in cash, up from $1.6 million in 2024.
- Preliminary Phase 1b/2 data expected in 1H 2027, with Phase 3 initiation targeted by end of 2027.
- Net loss narrowed to $43.4 million in 2025 from $69.2 million in 2024, driven by lower R&D expenses despite higher G&A from public company costs.
- No revenue generated; company remains in clinical development phase.
Financial Impact
Cash position increased by $116.4 million YoY, primarily from financing and merger activity. R&D spend decreased to $30.8M from $45.0M due to one-time 2024 royalty payment. Net loss reduced by $25.7 million.
Risk Factors
- Clinical development risk: early-phase data may not translate to Phase 3 success.
- Dilution risk if future capital raises are needed beyond 2027.
- Competition from established anti-VEGF therapies and emerging long-acting agents.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3257073 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 1d ago | SC 13G | $1.80 | awaiting T+60 | — | $1.86 (+3.33%) |
Aug 11, 2026 11w ago | 8-K | $3.97 | awaiting T+60 | — | $1.86 (−53.15%) |
Aug 11, 2026 11w ago | Press Release | $3.97 | awaiting T+60 | — | $1.86 (−53.15%) |
Aug 3, 2026 12w ago | 3 | $4.32 | awaiting T+60 | — | $1.86 (−56.94%) |
Jul 20, 2026 14w ago | 8-K | $4.00 $2.23 | ▼ −44.25% | ▼ −49.09% | $1.86 (−53.50%) |
Jul 17, 2026 14w ago | 8-K | $4.38 $2.26 | ▼ −48.40% | ▼ −53.09% | $1.86 (−57.53%) |
Jul 17, 2026 14w ago | Press Release | $4.38 $2.26 | ▼ −48.40% | ▼ −53.09% | $1.86 (−57.53%) |
Jun 11, 2026 19w ago | Institutional Cluster | $4.36 $3.90 | ▼ −10.55% | ▼ −14.95% | $1.86 (−57.34%) |
May 12, 2026 24w ago | 8-K | $4.79 $4.19 | ▼ −12.53% | ▼ −16.91% | $1.86 (−61.17%) |
May 12, 2026 24w ago | Press Release | $4.79 $4.19 | ▼ −12.53% | ▼ −16.91% | $1.86 (−61.17%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers